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Background: Upon admission to a hospital patients’ medications are frequently switched to alternative drugs
compiled in so called hospital drug formularies. This substitution process is a laborious and error-prone task which
should be supported by sophisticated electronic tools. We developed a computerised decision support system and
evaluated benefit and potential harm associated with its use.
Methods: Based on a multi-step algorithm we identified drug classes suitable for exchange, defined conversion
factors for therapeutic interchange, built a web-based decision support system, and implemented it into the
computerised physician order entry of a large university hospital. For evaluation we compared medications
manually switched by clinical pharmacists with the results of automated switching by the newly developed
computer system and optimised the system in an iterative process. Thereafter the final system was tested in an
independent set of prescriptions.
Results: After iterative optimisation of the logical framework the tool was able to switch drugs to pharmaceutical
equivalents and alternatives; in addition, it contained 21 different drug classes for therapeutic substitution. In this
final version it switched 91.6% of 202 documented medication consultations (containing 1,333 drugs) automatically,
leaving 8.4% for manual processing by clinical professionals. No incorrect drug switches were found.
Conclusion: A large majority (>90%) of drug switches performed at the interface between primary and tertiary care
can be handled automatically using electronic decision support systems, indicating that medication errors and
workload of healthcare professionals can be considerably reduced.
Keywords: Clinical decision support systems, Drug information services, Drug switchingBackground
Drug switching at the interface between primary and ter-
tiary care is a time-consuming and error-prone task in
inpatient care [1]. In hospitals local drug committees
and pharmacies usually define hospital drug formularies
(HDF). HDF are restricted prescribing lists containing a
subset of all available drugs with the intention to assure
quality of in-house prescribing, simplify logistics, and
save costs in drug therapy [2,3]. Given the large size of* Correspondence: walter.emil.haefeli@med.uni-heidelberg.de
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reproduction in any medium, provided the orthe German drug market the likelihood of drugs being
on the HDF is small. Indeed, upon admission to a Ger-
man hospital about 50% of all previous drugs are
switched [1,4]. Appropriate switching is a laborious task
that must carefully consider combination products,
routes of administration, and also therapeutic equiva-
lents and their (often differing) doses, if the same active
ingredient is not available.
In a pilot investigation assessing the quality of drug
switching we evaluated 128 switches in 30 consecutively
admitted patients and learnt that one in five drug substi-
tutions (21%) was wrong, mainly due to dose errors or
mistakes in switching combination drugs to multipleral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Switch Algorithm. Standardised multi-step algorithm to
translate a drug regimen into appropriate alternatives contained in a
hospital formulary (modified from [1]).
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which compromised optimum treatment already on the
first day of hospitalisation, was alarming and we, thus,
decided to support the process of drug switching
electronically.
Computerised physician order entry (CPOE) and clin-
ical decision support systems (CDSS) have successfully
prevented prescription errors, improved patient out-
come, and reduced cost [5-9].
To implement a CDSS for drug switching upon admis-
sion we developed a multi-step algorithm and in a first
evaluation it qualified as a logical framework to ease the
practice of switching drugs in a standardised and reliable
way [1]. We then built a CDSS, based on the algorithm,
implemented it into the CPOE of a large university hos-
pital, and evaluated benefit and potential harm.
Methods
Development and implementation of the CDSS
The logical basis of our CDSS was a multi-step algo-
rithm that translates the drugs of a patient’s drug history
into a suitable alternative therapy [1] (Figure 1) that was
developed by an interdisciplinary team of specialists
(physicians, pharmacists, and computer scientists).
Briefly, in the first step the patients’ drug list is checked
for drugs listed on the HDF. In this case no switch is
necessary and the same drug is recommended. In a sec-
ond step the HDF is searched for pharmaceutical
equivalents, i.e. drugs with matching active ingredient
(drug parent), strength, and application form. If no
pharmaceutical equivalents are available, the algorithm
seeks for pharmaceutical alternatives, i.e. drugs on the
HDF with the same drug parent but differing strength
and comparable dosage forms. Because of differing drug
strengths the CDSS must be able to modify the dosage
regimen adequately. If no pharmaceutical alternatives
are identified for a drug the HDF is checked for thera-
peutic equivalents (Figure 2), defined as exchangeable
drugs with differing parents within the same drug class.
Drugs within a drug-class can differ widely in potency
and efficacy [10,11], which has to be considered during
exchange to avoid over- and underdosing. Therefore,
21 drug classes were defined eligible for automatic
interchange and corresponding dose conversion factors
were extracted from the literature (Table 1). If no head-
to-head comparison of a switch pair was published, con-
version factors were derived from the approved mainten-
ance doses as published in the summary of product
characteristics (SPC). These classes usually contained
drugs of a common Anatomic Therapeutic Chemical
(ATC) classification system group (e.g. calcium-channel
blocking agents; Table 1) and concurrently considered
approved medical indications of the compound to be
switched. Hence, if calcium channel blockers were to beswitched, the system did not suggest the substitution of
felodipine (indication: hypertension) with nimodipine
(indication: prevention of cerebral vasospasm) because
of the differing labelled indications. If a drug was
approved for more than one indication (e.g. ramipril for
hypertension, heart failure, diabetic nephropathy, and
others) and conversion factors of different indications
differed, this fact was indicated. In the final step the
remaining drugs, not handled in previous steps, were
categorised as not suitable for automatic switching thus
requiring manual checking by a physician or pharmacist
for possible alternatives, discontinuation, or external
ordering of the brand.
Based on this algorithm we implemented a web-based
CDSS and integrated it into the existing CPOE (AiD-
KlinikW) used at the University Hospital of Heidelberg.
For technical development we used PHP (PHP: Hyper-
text Preprocessor) and AJAX (Asynchronous JavaScript
and XML) for the user interface (Figure 3), a MSSQL
Figure 2 Substitution of therapeutic equivalents. Switch of a drug to a therapeutic equivalent within the same drug class and corresponding
dose adjustment using dose conversion factors.
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2005) for data storage, and an IIS Webserver (Microsoft
Internet Information Services 6.0) for providing the
system to all 5,500 clients within the hospital. The
required pharmaceutical and pharmacological knowledge
was entered into the CDSS database using Microsoft
Access 2003 data entry forms.Table 1 Drug classes integrated into the final CDSS
version for automatic switching to therapeutic
equivalents
Drug class ATC code(s)
Antacids A02AA, A02AB, A02AC,
A02AD, A02AF, A02AH
Histamine H2-receptor antagonists A02BA
Proton pump inhibitors A02BC
Serotonin (5-HT3) antagonists A04AA
Blood glucose lowering drugs, excl. insulins A10BB, A10BG




Sulfonamides, plain (low-ceiling diuretics) C03BA
Sulfonamides, plain (high-ceiling diuretics) C03CA
Beta-blocking agents C07AA, C07AB, C07AG
Calcium-channel blocking agents C08CA
Angiotensin-converting enzyme inhibitors C09AA
Angiotensin receptor antagonists C09CA
HMG-CoA reductase inhibitors C10AA
Fibrates C10AB
Alpha-adrenoceptor antagonists G04CA
Selective serotonin (5-HT1) agonists N02CC
Benzodiazepine (anxiolytics) N05BA
Benzodiazepine (hypnotics and sedatives) N05CD
Benzodiazepine related drugs N05CF
ATC: Anatomic Therapeutic Chemical classification system.To implement the described algorithm, well structured
data of all available drugs of the German market were
necessary. Based upon this data (MMI Pharmindex,
Medizinische Medien Informations GmbH, Germany)
the CDSS compares different brands regarding import-
ant drug characteristics such as active ingredients,
strengths, dosage forms, and ATC classification and also
switches combination products. Depending on the step
of the algorithm further subroutines of the CDSS pro-
vide additional data to be displayed (e.g. newly adjusted
dosage regimens, information about tablet splitting, or
hints and warnings related to the suggested substitution
(Figure 3)).
Evaluation of the CDSS
In some surgical wards of the University Hospital of
Heidelberg switching drugs on admission is routinely
performed by a team of clinical pharmacists. Therefore
the patient’s drug history is documented by nurses or
physicians of the surgical ward and faxed to the hospital
pharmacy where the drugs are switched manually to
drugs of the HDF. The resulting suggestion for in-house
medication is faxed back to the requesting ward and
documented on paper. These previously and independ-
ently documented medication switches were used to test
the functionality of the newly developed CDSS (version
0.9). The medications of consecutively documented drug
switch consultations of a three-month period were
entered into the CPOE and the manual switches by the
clinical pharmacists were compared with the suggestions
of the electronic CDSS.
Because some drugs may be switched to more than
one compound of the HDF each switch was evaluated by
an independent senior clinical pharmacist who was
blinded for the origin of the switch. The main goal of
this comparison was to decide whether the switching
results were identical, equivalent or whether either one
suggestion was better. All switching results of the CDSS
that were considered worse were reviewed once again by
Figure 3 Screenshot: CDSS for automatic switching of drugs. Drugs prescribed to the patient before admission are listed on the left and the
correspondingly switched drugs are shown on the right. The figure shows five examples of drug switches originating from the single steps of the
algorithm (step 1–5). In example 2 an additional warning is displayed informing about differing indications of the switched drugs, in example 3 a
combination drug is switched to two single agents. In example 4, the switch to a therapeutic equivalent required dosage adjustment (20mg
simvastatin qd→ 40mg pravastatin qd), and in example 5, no alternative could be suggested.
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CDSS suggestion was inadequate/wrong or correct but
suboptimal.
On the basis of this assessment the CDSS was slightly
modified to further improve the software (version 1.0).
Then the evaluation was repeated in an independent set
of consecutive switch consultations documented in the
three months following the first evaluation period.
Data collection and analysis
This study was approved by the responsible Ethics Com-
mittee of the Medical Faculty of Heidelberg University,
Germany (protocol # 136/2005) and conducted accord-
ing the principles of the current version of the Declar-
ation of Helsinki. Only anonymised prescription data of
switch consultations were used for this study. Data were
described with descriptive statistics and reported as ab-
solute and relative frequencies or arithmetic means withstandard deviation (SD). Data entry and analysis were
performed on a Microsoft SQL Server 2005 database by
using structured query language (SQL) and by using
Microsoft Excel 2003.
Results
Pilot evaluation of the CDSS (version 0.9)
In the first evaluation 174 documented drug switch
consultations were included containing 1,296 drugs
manually switched by the team of clinical pharmacists
(mean ± SD: 7.5 ± 4.3 drugs per consultation). 1,176 of
these (90.7%) could be entered into the evaluation-
database; the remaining 120 (9.3%) were excluded because
essential information was missing on the handwritten
consultations (e.g. drug strength or dosage regimen).
Of these 1,176 drugs 807 (68.6%) were substituted
similarly by clinical pharmacists and the CDSS, i.e. iden-
tical drugs and dosage regimens were suggested. In the
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ent dosage regimen resulted from automatic and manual
switching. The blinded review of these by an independ-
ent expert revealed that in 42.0% of these cases sugges-
tions of pharmacists and CDSS were equivalent, in
27.1% the CDSS suggestions and in 30.9% the pharma-
cists’ suggestions were considered superior. The detailed
analysis of the latter group (30.9%) revealed that 78.1%
of these CDSS suggestions were correct yet inferior to
the pharmacists’ recommendations and 21.9% of the
suggestions were inadequate or wrong, prompting modi-
fication of the first CDSS version. Hence, of the 1,176
switches that could be assessed 25 (2.1%) required modi-
fication. Weaknesses of version 0.9 of the CDSS mainly
concerned four drug classes which were consequently
excluded from automatic substitution:
1) “Insulins” (ATC code: A10A): Substitution of insulins
should be personalised with a tailored monitoring of
blood-glucose levels.
2) “Alpha-adrenoceptor blockers” (ATC code: C02CA):
To switch alpha-adrenoceptor blockers a change of
the dosage form and thus release characteristics (e.g.
slow → instant release) can be necessary which is
not yet supported by the given algorithm.
3) “Drugs for treatment of hyperkalemia and
hyperphosphatemia” (ATC code: V03AE): In this
group various agents with differing mechanisms of
action are clustered that require manual processing
(e.g. calcium carbonate → calcium diacetate).
4) “Other antianemic preparations” (ATC code:
B03XA): In this group diverse chemical classes (e.g.
biosimilars) are clustered that require processing by
experts.
In the revised tool only oral dosage forms were consid-
ered thus omitting parenteral and inhaled drugs.
Evaluation of the final CDSS (version 1.0)
The evaluation of the refined CDSS version comprised
202 documented drug switch consultations containing
1,518 drugs (7.5 ± 3.9 switches per consultation). Of
these 185 prescriptions (12.2%) were incomplete or in-
accurate and thus excluded leaving 1,333 drug switches
(87.8%) for evaluation.
947 of 1,333 drugs (71.0%) were substituted similarly
by the team of pharmacists and the CDSS. Differences in
automatic and manual switching occurred in 386 cases
(29.0%). For 58.6% of these cases suggestions of pharma-
cists and CDSS were equivalent, in 15.5% the CDSS sug-
gestions and in 25.9% the pharmacists’ suggestions were
considered superior. The review of the latter discrepant
suggestions revealed that all suggestions by the CDSS
were correct, but not always the optimum choice, and inno instance (0%) inadequate equivalents were suggested.
The results of both evaluations (version 0.9 and 1.0) are
summarised in Figure 4.Switching performance of the CDSS
Ultimately the final version (version 1.0) was able to cor-
rectly suggest drugs of the HDF in 91.6% of all cases. In
31.7% the initial drug was identical with a drug of the
HDF. In 40.7% an appropriate alternative with identical
drug parent and strength was identified, and in 12.2% an
alternative with identical parent but differing strength
was found. In 7% a substitute with a different parent of
the same drug class was suggested and equivalent doses
were calculated. Only in 8.4% of all cases no substitute
was found automatically thus requiring manual handling
by an expert (Table 2). These latter drugs mainly
belonged to the excluded drug classes, contained com-
bination products with multiple active ingredients (>3),
or did not meet other criteria necessary for automatic
substitution (i.e. only solid oral dosage forms were
switched to therapeutic equivalents ignoring e.g. inhaled
compounds). Finally in some cases no possible substi-
tutes were available and these brands had to be ordered
from external suppliers.Discussion
In Germany close to 18 million people are hospitalised
every year [12] and according to their drug history they
are prescribed an average of six drugs [1,13]. Hence,
every day roughly 300,000 drug switches are performed
in German hospitals and – if performed with similarly
poor accuracy as in our pilot study – they will be a
major cause for avoidable risks for patients and also a
waste of working force.
The potential for medication errors concerning dose
adjustments after switching to therapeutic equivalents is
well known. In an American study a significant propor-
tion of patients whose cholesterol lowering medication
was switched from atorvastatin to simvastatin thereafter
received lower therapeutic doses, potentially impairing
the quality of care and effectiveness [14]. But in some
cases also the appropriateness of generic substitution is
still controversially discussed [15,16]. Even when thera-
peutic doses and conversion factors are carefully consid-
ered the substitution may lead to critical changes in the
exposure with additives [17,18] and – given the generally
accepted range of bioequivalence – switching may cause
considerably differing exposures to the active compound,
which may be relevant for drugs with a narrow thera-
peutic window [15]. Therefore tight regulations and
recommendations defining suitable drugs and drug
classes for substitution might improve physicians’ confi-
dence and compliance in the switching procedure [15].
Figure 4 Results of the evaluation. Results of the pilot and final evaluation of the CDSS (computerised decision support system). The
evaluation was performed by comparing the switch suggestions of the CDSS with those of the clinical pharmacists (CP). CP = CDSS: Drugs
substituted similarly by CP and CDSS. CP ≠ CDSS: Relevant differences in automatic and manual switching. CP < CDSS: Suggestion of CDSS is
better. CP ≈ CDSS: Both suggestions are considered appropriate. CP > CDSS: Suggestion of CP is better. CDSS ok: Suggestion of CDSS correct
but inferior to suggestion of CP. CDSS not ok: Suggestion of CDSS inadequate/wrong.
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specialists (physicians, pharmacists, and computer scien-
tists) to design and develop an electronic tool, which is a
standard procedure to create well-fitted and user-
friendly systems [19]. After implementation we evaluated
a large independent sample of prospectively documented
drug switches performed by experienced clinical phar-
macists and thus used real clinical data as the most real-
istic test-cases.
The first test of our newly developed CDSS already
showed good performance of our algorithm (93.6% couldbe switched electronically) but also revealed weaknesses
that might have led to medication errors if the CDSS
would have been released into clinical routine before
meticulous validation. These weaknesses mainly albeit
not exclusively concerned the switch to therapeutic
equivalents, which in some cases required additional pa-
tient information or a switch to formulations with differ-
ing release characteristics. After modification, the
second version (version 1.0) of the CDSS enabled auto-
matic switching of 91.6% of the cases without any inad-
equate suggestions. Considering the huge size of the















Σ: CDSS-switch 93.6%* 91.6%
Group 5: No CDSS-switch 6.5%* 8.4%
*>100.0% due to rounding.
CDSS: Clinical decision support system, HDF: Hospital drug formulary.
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rather remarkable. Indeed with more than 70,000 phar-
maceuticals, Germany has one of the largest drug
markets worldwide suggesting that the CDSS will likely
also efficiently switch drugs prescribed in other coun-
tries. Such a CDSS may even be useful in countries
whose reimbursement system currently allows continu-
ation of the patient’s own drugs during hospitalised care
(such as the UK) because even then formulary substitu-
tions are still required for example when patients are
admitted as emergencies or if there is insufficient quan-
tity of medicine to cover the whole inpatient stay.
Even in the optimised version, some drug switches
suggested by the CDSS (100/1,333 observed switches)
were judged inferior to the switching result of the clin-
ical pharmacists. Analysis of these situations revealed
that in most cases the clinical pharmacists derogated
from the basic algorithm to improvise in a non-standard
situation. For example our CDSS failed to compute an
adequate dosage regimen after switching “Metoprolol
100 retard 1A Pharma” (containing 78.09 mg metopro-
lol) to “Beloc-Zok Retardtabl” (containing 77.82 mg
metoprolol) because of slightly differing drug strengths,
whose clinical irrelevance is easily recognised by an ex-
pert but requires proper specification for consideration
by a computer system. Furthermore the human specialist
is able to consult information sources beyond the CDSS
database (e.g. by contacting the pharmaceutical manufac-
turer when additional drug information is needed and not
available electronically). At last and in contrast to a CDSS,
clinical pharmacists were able to consider special patient
characteristics (e.g. age/mental state) and therefore to
adjust a dosage regimen seeking to simplify the prescrip-
tion (e.g. by avoiding tablet splitting). Indeed complex
and complicated drug regimens (e.g. regimens with mul-
tiple administration times or the need for tablet-splitting)
are an important prescription characteristic promoting
non-adherence of the patients [20,21] that could be pre-
vented in a large fraction of all prescriptions [22].This emphasises areas of unmet need among profes-
sionals for support of drug switching in complicated
cases that are not yet covered by the CDSS. Neverthe-
less, already today the CDSS can reduce the workload
of these professionals by reliable handling of the large
majority of routine substitutions. This is a substantial
reduction of time when considering that manual drug
switching by American clinicians was estimated to take
11 minutes per medication [23].
The thorough analysis of drug pairs not yet automatic-
ally switched revealed that a meaningful next step would
be to support dose adjustment of different application
forms and to consider combination products for thera-
peutic substitution (step 4). In addition, a future switch-
ing tool could also enable adoption of new scenarios like
patient admission to an intensive care unit where oral
forms often have to be switched to parenteral or intra-
venous forms and the switch back to ambulatory medi-
cation at discharge from hospital.
Limitations
A number of potential limitations should be considered
before generalisation of the results to other settings. (1)
In our study we only switched drug combinations of sur-
gical patients thus restricting evidence to patients receiv-
ing comparable medication regimens. However, as
shown in our previous evaluation performed in the same
wards [1], the Charlson score of these patients is high,
reflecting the numerous co-morbidities of these patients
and suggesting that their drug regimens likely represent
also a population of internal medicine patients. (2) In
our evaluation we had to exclude about 10% of the
switch requests because essential details of the patients’
prescription were missing (e.g. missing dosage regimen,
strengths, or information needed to identify the specific
brand). This stresses the advantages of an electronic
documentation of patient medications in a CPOE linked
to drug databases as it enables exact identification of
brands, the key information to relevant drug-related data
like drug composition, strength, galenic formulation, and
the corresponding SPC [24]. Unfortunately SPC infor-
mation is currently not available in a well structured for-
mat [25], which would facilitate the development of
tools like the one described herein. (3) Our evaluation
was conducted by project members and not by clinical
staff for whom the CDSS was developed. Thus, possible
socio-technical incidents, a group of medication errors
originating from interactions between clinical staff and
the system [26], have yet to be investigated. (4) Finally
the revision of differences between the switching results
of pharmacists and the CDSS was performed by only
one expert. This senior clinical pharmacist was consid-
ered best choice due to her extensive practical experi-
ence in switching drugs for years. However, by blinding
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(pharmacist or CDSS) bias is minimised.
Conclusions
The results of our study demonstrate that in the over-
whelming majority of cases (>90%) a sophisticated elec-
tronic CDSS can safely and reliably switch drugs of
admitted patients to the locally available drugs as com-
piled in a HDF. Given the substantial error-rates in this
process such support is indeed needed.
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